AMD

Influence of Mediterranean-Style Diet on AMD

Our findings suggest certain dietary and lifestyle habits may confer long-term protective benefits.

Christopher Phung, BA; Beryl Zhou, BS; Robert Luca, BA; and Dimitra Skondra, MD, PhD

Predicting Progression to GA Using Imaging Biomarkers

Several OCT findings can help clinicians better understand a patient’s risk of progression to sight-threatening disease.

Kelly Donovan, MD, PhD, and Eleonora M. Lad, MD, PhD

PBM for AMD: Mechanisms, Evidence, and Clinical Integration

Photobiomodulation shows promise, but long-term data are needed.

Luis Acabá-Berrocal, MD, and Anton Orlin, MD

The AMD Space Race

Allen C. Ho, MD; Robert L. Avery, MD; and Lejla Vajzovic, MD

Novel MOAs in Wet AMD

The pipeline is full of therapies that hold promise for extending treatment efficacy.

Lejla Vajzovic, MD, FASRS; Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi

Pearls and Pitfalls of Treating GA and Wet AMD

Concurrent therapy can pose clinical challenges. Here’s how you can manage these patients and maximize outcomes.

Sean D. Adrean, MD, FAAO, and Wesley Han, BS

Landmark Trials in AMD

A summary of the clinical trials that have shaped—and continue to shape—how we treat AMD.

Saghar Bagheri, MD, PHD; Alberto Quarta, MD; Rouzbeh Abbasgholizadeh, MD; Alessandro Feo, MD; Paolo Forte, MD; David Sarraf, MD; Michael S. Ip, MD; and SriniVas R. Sadda, MD, FARVO

Retina Then and Now: March Spotlight

As part of our 20th anniversary, Retina Today is digging into the archives to reflect on how much the profession has changed.

Robert L. Avery, MD

Optogenetics: Bringing Light to the Blind

A primer on the mechanism of action and what’s in the pipeline.

Vinit B. Mahajan, MD, PhD

Anti-VEGF and Beyond: Expanding Therapeutic Options for Wet AMD

A 2025 review of clinical trials evaluating novel therapies for wet AMD.

Matthew Elitt, MD, PhD; Pariyamon Thaprawat, BS; and Nita Valikodath, MD, MS

Trials and Innovations in Geographic Atrophy Therapy

Novel mechanisms of action and delivery methods hold promise for patients with dry AMD.

James M. Harris, MD, PhD, and Eleonora M. Lad, MD, PhD

A Series of Rare Events in Geographic Atrophy Therapy

These cases highlight screening and follow-up considerations with anti-complement therapy.

Tina Tang, MD, and Nauman Chaudhry, MD

Retina by the Numbers

Allen C. Ho, MD, and Robert L. Avery, MD

Beyond Complement: Emerging Therapeutics for Dry AMD

Targeting inflammation, mitochondrial health, and neuroprotection.

Aumer Shughoury, MD, and Thomas A. Ciulla, MD, MBA

Gene Therapy for AMD: What You Need to Know

Several candidates with varying mechanisms of action and delivery methods are in clinical trials.

Szilárd Kiss, MD, FASRS, and Peyman Razavi, MD

Imaging Biomarkers for GA Progression

Our study identified a set of OCT parameters that can predict a faster growth rate.

Maxwell S. Mayeda, MD, and Talisa E. de Carlo Forest, MD

Emerging (Durable) Therapies for Wet AMD

New approaches are helping us care for patients while reducing their treatment burden.

Jacob S. Heng, MD, PhD, and Adrienne W. Scott, MD

FDA Guidance: What it Means for AMD Trials

Industry leaders discuss the shifts in clinical trial designs and their recent interactions with the FDA.

Nadia K. Waheed, MD, MPH; Ramiro Ribeiro, MD, PhD; Victor Chong, MD, MBA, FARVO; Lanita Scott, MD; and David J. Tanzer, MD

Wet AMD Therapies in the Pipeline

A review of clinical trials investigating novel approaches to wet AMD in 2024.

Saumya M. Shah, MD, and Daniel Su, MD

Geographic Atrophy Therapies to Watch

An update on complement inhibitors, gene and cell therapies, and novel approaches.

Rebecca Hepp, MA, Editor-in-Chief